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Abstract 
Background: Digital adherence technologies (DATs) are recommended to support patient-centred, differentiated 
care to improve tuberculosis (TB) treatment outcomes, but evidence that such technologies improve adherence is 
limited. We aim to implement and evaluate the effectiveness of smart pillboxes and medication labels linked to an 
adherence data platform, to create a differentiated care response to patient adherence and improve TB care among 
adult pulmonary TB participants. Our study is part of the Adherence Support Coalition to End TB (ASCENT) project in 
Ethiopia.
Methods/Design: We will conduct a pragmatic three-arm cluster-randomised trial with 78 health facilities in two 
regions in Ethiopia. Facilities are randomised (1:1:1) to either of the two intervention arms or standard of care. Adults 
aged ≥ 18 years with drug-sensitive (DS) pulmonary TB are enrolled over 12 months and followed-up for 12 months 
after treatment initiation. Participants in facilities randomised to either of the two intervention arms are offered a DAT 
linked to the web-based ASCENT adherence platform for daily adherence monitoring and differentiated response 
to patient adherence for those who have missed doses. Participants at standard of care facilities receive routine care. 
For those that had bacteriologically confirmed TB at treatment initiation and can produce sputum without induction, 
sputum culture will be performed approximately 6 months after the end of treatment to measure disease recurrence. 
The primary endpoint is a composite unfavourable outcome measured over 12 months from TB treatment initia-
tion defined as either poor end of treatment outcome (lost to follow-up, death, or treatment failure) or treatment 
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Background
Globally, an estimated 10.0 million people became ill 
with tuberculosis (TB) in 2019, with 7.1 million diag-
nosed, treatment success rate of 85%, and about 1.4 mil-
lion deaths [1]. TB treatment is the core of TB control 
and prevention, but poor adherence to treatment can 
lead to disease relapse, drug-resistance, and forward TB 
transmission [2]. Poor treatment outcomes are dispro-
portionately high in low-income countries and among 
low-socio-economic groups within countries [1]. The 
World Health Organization (WHO) End TB Strategy, 
in alignment with the Sustainable Development Goals 
(SDG), has set ambitious goals to end the global TB epi-
demic by 2035 [3]. This strategy requires high-impact 
interventions to ensure equitable access to high-qual-
ity diagnosis, treatment, care, and prevention, without 
imposing catastrophic costs, to people with TB.
The WHO-recommended Directly Observed Treat-
ment (DOT) approach has been the most widely imple-
mented strategy to support administration of TB 
treatment and ensure that patients successfully complete 
the treatment period. While significant improvements 
in TB treatment outcomes have been observed after 
the introduction of DOT, global treatment success rates 
for both drug-sensitive (DS)-TB and particularly drug-
resistant (DR)-TB remain below the 90% target for 2025 
set out in WHO’s End TB strategy [1, 3]. The implemen-
tation of facility-based DOT places a significant burden 
on both patient and health systems [4–7]. For patients, 
DOT is associated with stigma, loss of autonomy and lost 
income. For providers DOTS is resource intensive and a 
burden on busy health care facilities. Furthermore, the 
traditional DOT approach assumes that all TB patients 
require the same level of monitoring and support, rather 
than focusing care on patients that are at higher risk for 
non-adherence and poor outcomes, and therefore in 
need of intensified support [8].
Adherence to TB treatment is essential to attain dura-
ble cure and avoid the emergence of drug resistance [9]. 
It is also an important element of clinical trials of TB 
treatment as it strongly influences the treatment out-
come and therefore evaluation of the intervention [10]. 
While there are variations across studies in classifying 
adherence, definitions of adherence to TB treatment 
have emphasized patients’ roles in medication-taking 
throughout the treatment course following the recom-
mendations from the provider [2, 11]. Adherence to 
treatment has been shown to be influenced by patient 
characteristics, treatment regimen complexity, and the 
health care setting [2, 11], and the use of adherence 
interventions such as electronic medication monitors 
and mobile text messaging has shown to improve TB 
treatment outcomes [12–15]. Adherence technologies 
may be expected to vary in utility by patient character-
istics as well as cultural and health care setting.
Currently, a number of digital adherence technolo-
gies (DATs), such as electronic medication monitors 
and text messaging, are available, offering approaches 
to improve treatment adherence [16]. These technolo-
gies are digital tools that utilize mobile phone, com-
puter, web-based and/or electronic sensor technology 
to support patient care and adherence. These tech-
nologies often employ reminders to patients for tak-
ing treatment, as well as the capture of detailed, timely, 
patient-specific adherence data to be made available to 
the patient’s health-care provider for monitoring. Elec-
tronic medication boxes are medication monitoring 
devices (often with audio-visual reminders) that store 
TB medications and which record and transmit patient 
box access to give the provider the patients’ dosing his-
tory. The medication sleeve is also a type of electronic 
medication monitor that consists of medication blis-
ters wrapped in special envelopes with printed codes. 
Patients use these codes when making a toll-free call/
text to let their health care provider know when they 
have taken their medication [16]. Such digital innova-
tions are beneficial because they may remind patients 
to take their medications. Digital adherence technolo-
gies may be employed with a web-based platform to 
compile dosing histories that allow health-care provid-
ers to review adherence daily. Although the End TB 
Strategy recommends using digital adherence technol-
ogies, evidence that such technologies improve adher-
ence and treatment outcomes is still limited [17].
recurrence measured 6 months after the scheduled end of treatment. This study will also evaluate the effectiveness, 
feasibility, and cost-effectiveness of DAT systems for DS-TB patients.
Discussion: This trial will evaluate the impact and contextual factors of medication label and smart pillbox with a dif-
ferentiated response to patient care, among adult pulmonary DS-TB participants in Ethiopia. If successful, this evalua-
tion will generate valuable evidence via a shared evaluation framework for optimal use and scale-up.
Trial registration: Pan African Clinical Trials Registry PACTR202008776694999, https:// pactr. samrc. ac. za/ Trial Displ ay. aspx? 
Trial ID= 12241, registered on August 11, 2020.
Keywords: Tuberculosis, Smart pillbox, Medication label, Trial, Cluster randomised, Pragmatic, Ethiopia
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Recent randomised studies in countries in Africa and 
Asia documented mixed results regarding effectiveness 
of medication monitoring to reduce poor medication 
adherence and treatment outcomes [18–24]. However, 
it is not clear whether these findings can be generalised 
to real-life circumstances that are not reflected in ran-
domised controlled trials. Furthermore, the patient and 
health-care provider acceptability and uptake of these 
tools have been shown to be vary across countries and 
settings [25–27]. Cultural or material circumstances 
may operate differently on the utility or acceptability of 
DATs to deliver the targeted treatment support that is 
needed to meet the End TB goals. Data from individual 
trials might not typically provide policy makers with 
all the information needed to replicate their success in 
real-life settings and specific contexts.
Ethiopia is among the 30 high TB and TB/ HIV bur-
den countries, with annual estimated TB incidence 
of 157/100,000 populations and death rate of 19 per 
100,000 populations for 2019 [1]. Since 1997, Ethio-
pia has adopted Directly observed treatment, short-
course  (DOTS) as its core treatment strategy, with the 
development of the first combined Tuberculosis and 
Leprosy Prevention and Control Program manual [28] 
and the national control program endorsed the global 
STOP TB and END TB strategies over subsequent years 
[28, 29]. However, non-adherence to TB treatment 
and poor treatment outcomes remain the major bar-
riers to achieve the national END TB Strategy targets 
[30–32]. As TB remains a public health problem with 
significant burden among affected and at-risk popula-
tions in Ethiopia, the country’s national strategic plan 
recommends evidence-based and high-impact inter-
ventions that will keep the nation on track to end the 
TB epidemic [29]. The implementation of DATs has the 
potential to promote a cost-effective, patient-centred 
approach to improve TB treatment adherence across a 
range of settings and thereby reduce TB incidence and 
mortality to end TB as a public health problem. The 
Adherence Support Coalition to End TB (ASCENT) 
Consortium members [Koninklijke Nederlandse Cen-
trale Vereniging (KNCV) Tuberculosis Foundation, The 
Aurum Institute, London School of Hygiene & Tropi-
cal Medicine, and Program for Appropriate Technology 
in Health (PATH)] in partnership with the govern-
ments of five countries (Ethiopia, Philippines, South 
Africa, Tanzania, and Ukraine) are implementing the 
ASCENT project, that will contribute evidence to sup-
port the adoption and uptake of DATs. In Ethiopia, 
this evidence will be generated through a pragmatic 
cluster randomized trial to implement and assess the 
effectiveness of medication labels and smart pill boxes 
linked to a web-based adherence platform, to create a 
differentiated care response to patient adherence and 
improve TB care among adult pulmonary DS-TB 
participants.
Objectives
The primary objective of the trial is to evaluate whether 
implementation of daily adherence monitoring using 
either smart pill box or medication label, with differen-
tiated response to patient adherence, decreases the pro-
portion of adult pulmonary DS-TB participants with 
unfavourable outcomes (defined as poor end of treatment 
outcome or recurrence up to 6 months after the sched-
uled end of treatment) compared with the standard of 
care. The secondary objectives are to describe longitu-
dinal DAT engagement and fidelity to adherence tools, 
project the epidemiological impact of scale-up of the 
interventions, estimate the cost-effectiveness and explore 




This is a pragmatic three-arm cluster randomised trial 
(CRT) with the health facility as the unit of randomisa-
tion. A total of 78 health facilities from two regions are 
included in the trial. Health facilities were randomised 
(1:1:1), using stratification and restriction, to either the 
(i) smart pill box or (ii) medication label, both with daily 
monitoring and differentiated response to patient adher-
ence, or (iii) standard of care.
Study setting
Ethiopia is administratively divided into ten regional 
states and two chartered cities. The trial will be con-
ducted in Addis Ababa city (the capital of Ethiopia) and 
Oromia region. These geographical settings were chosen 
in consultation with the National TB Programme (NTP) 
and the health facilities were selected in collaboration 
with NTP and the respective Regional Health Bureaus. 
The study health facilities include both large and small, 
urban, and rural facilities.
Study population
All adult pulmonary DS-TB participants in the selected 
78 health facilities who fulfil the following inclusion cri-
teria will be invited to participate: aged 18 years or over, 
expecting to stay in the study area for at least 12 months, 
not requiring hospitalization, and providing consent. All 
who consented will be followed up for 6  months after 
treatment completion.
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Intervention
Participants in facilities randomised to either of the two 
intervention arms will be offered a smart pill box or med-
ication label linked to the ASCENT web-based adher-
ence platform for treatment adherence monitoring.
Intervention arm 1: smart pill box
Participants in this arm will receive a smart pill box 
(evrimed 1000c), known also as Medication Event 
Reminder Monitor System (MERM). Dosing instruc-
tion and anti-TB drugs will be placed inside of the box. 
The box enables a configurable audio-visual reminder 
at a pre-defined time based on participants’ preference. 
When participants open the box, the embedded elec-
tronic device sends a signal in real-time to automatically 
log their daily dose to the ASCENT web-based applica-
tion via a built-in mobile internet connection. If con-
nectivity is temporarily unavailable, opening events are 
stored in the device memory and uploaded automatically 
when internet connectivity resumes. This allows the TB 
care provider to use the ASCENT adherence data plat-
form to evaluate daily dosing and offer differentiated care 
(Table 1) as appropriate.
Intervention arm 2: medication labels
Participants in this arm will have a label, containing a 
code unique to a 1-week period, placed on their fixed-
dose blister-packaged TB medication. When their daily 
dose is taken, participants will message this code using 
a toll-free text, which automatically logs their daily 
dose to the ASCENT web-based application. With the 
adherence data collected to the platform, the same pro-
cedure is used as for intervention arm 1 for offering dif-
ferentiated care (Table  1), as appropriate. Participants 
who do not have access to a mobile phone will be given 
a smart pill box.
Originally the medication sleeve approach as used in 
the Uganda stepped-wedge trial [19] was planned, but 
due to frequent changes in the dimensions of the pack-
aging used for TB medication which was also difficult 
to forecast, the label approach was adopted instead.
Standard of care
Participants in the control arm, will utilize the stand-
ard of care for TB treatment support in the facilities 
randomized to this arm. During the intensive phase of 
treatment, this entails direct observation of medication 
intake by a health worker or TB treatment supporter, at 
a health facility (hospital, health center or health post), 
at patient’s workplace, residence institution or home. 
During the continuation phase, medication intake is 
under direct observation by a TB treatment supporter 
or through self-administration upon consultation with 
the TB provider. Missed clinic appointments should 
result in a phone call to the patient and missing two 
consecutive clinic appointments should prompt a home 
visit by a health care worker (HCW).
Table 1 Differentiated care response to patient adherence in intervention arms
SMS short message service; HCW health care worker
*Among patients with a mobile phone; **If daily DOT resumes as the standard of care, phone calls will be replaced with escalation to community health worker for 
home visit; *** among patients with mobile phone access (either their own or treatment supporter)
Trigger Intervention
Dose recorded (daily) Medication label: message confirmation from patient of recorded dose
Smart pill box: box opening (sound and/or light)
Patient missed daily dose (1 day) Same day: patient receives a reminder SMS at 3 pm*
Next day: HCW will receive a notification of patients with a missed dose on 
their Task List
Follow-up actions: phone call to patient or treatment supporter, unless 
HCW is aware of a network issue**
Missed daily dose (2 consecutive days) Same day: patient receives a reminder SMS at 3 pm*
Next day: HCW will receive a notification of patients with a missed dose ion 
their Task List
Follow-up actions: phone call to patient or treatment supporter**, unless 
HCW is aware of a network issue***
Patient persistently missed doses (≥ 5 consecutive doses or multiple 
times)***
Escalation to community health worker for home visit using a standardised 
set of messages and counselling
Patient persistently missed doses (> 14 consecutive doses or multiple 
times missing 7 doses)
Discontinuation from DAT intervention and switch to daily DOT under the 
HCWs observation for TB patients with persistent non-adherence will be 
considered
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Differentiated care delivery based on adherence 
to treatment
Participants in the intervention arms will have their 
daily adherence data from their DAT recorded on the 
ASCENT adherence platform.
TB care providers can remotely access and review their 
participants adherence data through the ASCENT adher-
ence platform mobile Android app. Through this app, 
the TB care providers can see the day of treatment and 
medication taking history for patients on treatment for 
TB at their facility. It has built in data analytics to easily 
visualize and identify which participants have not taken 
their daily dose on a patient level dosing calendar. TB 
care providers offer interventions according to the num-
ber of doses a patient has missed. Table 1 summarizes the 
activities related to differentiated care response.
Randomization
Stratified, restricted randomisation of health facilities 
was used to ensure reasonable baseline balance between 
the intervention arms and standard of care arm [33]. 
Stratification was on region and treatment outcomes in 
2017–2019 (from the NTP TB registers), which divided 
the study facilities into four groups. The restrictions fur-
ther considered data from all study facilities’ NTP TB 
registers and included percentage with poor treatment 
outcome; number of DS-TB registrations; HIV preva-
lence among DS-TB and urban/rural facility.
Trial outcomes
The primary endpoint is a composite unfavourable out-
come, similar to previous TB treatment trials [34–36] 
and the DAT intervention being evaluated in China [37], 
defined as either a (i) poor end of treatment outcome 
(lost to follow-up, death or treatment failure or (ii) treat-
ment recurrence measured 6 months after the scheduled 
end of treatment). The secondary outcomes are:
Among adult pulmonary DS-TB participants in all 
arms:
 (i) Poor end of treatment outcome (defined as above).
 (ii) Lost to follow-up during treatment.
Among adult pulmonary DS-TB participants in inter-
vention arms
 (i) Longitudinal technology engagement with the 
DAT.
 (ii) Fidelity to the DAT (includes the number of mes-
sages sent to participants and HCWs, number and 
length of phone calls to and from participants, 
number of health facility visits by participants and 
number of home visits to participants as well as 
describing device failures, inability to engage with 
the technology and cell phone access).
TB patients enrolled in the trial TB care providers and 
key stakeholders will also be interviewed to explore the 
institutional feasibility and acceptability of implementing 
the DAT.
Impact modelling
The trial results will be used to inform a Mycobacterium 
tuberculosis transmission model for Ethiopia, which will 
be used to project the expected long-term epidemiologi-
cal impact if the interventions were to be scaled up across 
the country. This model will include treatment pathways 
to calibrate DS-TB incidence and mortality in Ethiopia, 
including a detailed description of the treatment pathway 
and implementation of DAT. The model outcomes will 
include the impact of the interventions on TB deaths and 
cases averted, as well as TB patient costs averted through 
a potential reduction in clinic visits required.
Economic evaluation
The effectiveness, utilisation, and cost data collected dur-
ing the trial will be used to estimate the cost-effectiveness 
of the (i) smart pill box with differentiated care and (ii) 
medication label with differentiated care when compared 
against the standard of care for DS-TB patients in Ethio-
pia. A societal perspective will be taken in the analysis, 
estimating the cost to the provider of providing the ser-
vice plus the costs incurred by patients in using the ser-
vice. Provider costs will include the above service-level 
costs, specifically the costs of training and supporting the 
implementation of the intervention. Since TB dispropor-
tionately affects patients of lower socio-economic status, 
TB prevention through effective treatment adherence 
may change how TB is distributed across socioeconomic 
strata in a population. Using the results of the trial dif-
ferentiated by socioeconomic status, we will quantify 
trade-offs related to health inequality in the decision to 
implement DATs by conducting a distributional cost-
effectiveness analysis [38].
Sample size calculation
Using facility-level TB treatment outcome data from 
2018 in the ASCENT facilities, overall poor treatment 
outcome was observed to be 17% which was higher than 
the overall proportion reported in Ethiopia in 2017. Since 
our study will also capture recurrence 6 months after the 
end of treatment, we have assumed the percentage with 
unfavourable outcome varies between 17 and 20%.
Assuming 26 facilities per arm (78 in total), a harmonic 
mean of 50 TB patients across facilities, a type I error of 
5%, percentage with unfavourable outcome in the stand-
ard of care of 17% and 20%, the trial will have 80 and 85% 
power to detect a one third reduction in the unfavour-
able outcome with a coefficient of variation (k) of 0.35 
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and k ≤ 0.3, respectively. We anticipate enrolling a total 
of around 4000 participants from all study facilities. All 
adult patients diagnosed with pulmonary DS-TB will be 
asked to participate in our study.
Study procedures
All patients visiting the TB clinic of the health facilities 
will be screened for eligibility (criteria described in the 
study population) by the TB care provider, and if eligi-
ble, will be offered enrolment in the ASCENT study and 
followed by written informed consent (see Additional 
file 1 for informed consent form and patient information 
sheet). Among those who have consented, a brief socio-
demographic case report form (CRF) will be filled out 
with the patient by the health care provider (as trained by 
the study team). In addition, contact details will also be 
collected to implement the intervention in the two inter-
vention arms and to facilitate follow-up 6  months after 
the end of treatment in all three arms (see Additional 
file 2 for completed SPIRIT checklist).
All participants will be treated according to Ethiopian 
NTP guidelines, which is a fixed dose combination of iso-
niazid, rifampicin, ethambutol, and pyrazinamide for the 
2-month intensive treatment phase, followed by isonia-
zid and rifampicin for the 4-month continuation phase 
[28]. At treatment initiation, all participants receive basic 
counselling on TB by the health facility staff according to 
routine practice, to improve their understanding of their 
illness, including the need for daily medication for the 
full 6-month duration of their treatment. Prior to patient 
enrolment, staff from both intervention facilities and 
standard of care facility will be invited to training that 
will standardize the information given to participants 
regarding TB disease and the importance of adherence. 
In addition, setting-appropriate information booklets will 
be provided to TB participants in intervention arms and 
posters for health facilities in all three arms.
Participants in intervention arm 1 (smart pill box) will 
be given a smart box, 14 days of medication, and a DAT 
booklet placed inside the smart box. At each opening, the 
box sends a signal to ASCENT platform and a daily digi-
tal log will be kept. Participants are requested to bring 
the box every 2  weeks during their 1st month of treat-
ment and monthly thereafter for refill and return the box 
after treatment completion, i.e., 6 months after treatment 
initiation. Participants in intervention arm 2 (medica-
tion label) will be provided with 14 days of medication, a 
medication label with a number code, and a DAT book-
let. The same refill schedule is used as for intervention 
arm 1 (smart pill box). Participants will be asked to send 
the number written on the medication label via short 
message service (SMS) to a standard number printed on 
the label every day after taking their daily dose. In the 
intervention arms, adherence data will be collected via 
the DAT on the ASCENT adherence platform, and TB 
care providers will use these data to offer patient-centred 
care. Participants in the intervention arms will also be 
offered educational and motivational messages through 
SMS. In addition, TB care providers will assist the par-
ticipants to resolve any problems related to the DAT, 
as necessary. Participants in the intervention arm who 
decline to participate and participants in the standard of 
care arm will follow the standard care for TB treatment 
supervision as per the NTP (Table 2).
As per the Ethiopian NTP guidelines [28], sputum 
will be collected at the 2nd and 5th month of treatment 
to monitor treatment response, and at 6th month upon 
treatment completion to determine treatment outcome. 
Treatment outcome data will be abstracted from the Unit 
TB Register. Participants who had an end of treatment 
outcome of cured or completed treatment will be con-
tacted by the study team via telephone around 6 months 
after treatment completion to check whether treatment 
for TB has been restarted. Participants who were bac-
teriologically confirmed pulmonary DS-TB at treat-
ment initiation will also be invited to attend the facility 
to give a sputum for culture to determine their TB dis-
ease status at 6-months post treatment. Participants will 
be reimbursed as compensation for their time and travel 
expenses.
Adverse consequences of study participation include 
a potential risk of inadvertent disclosure of TB status by 
possession of DATs associated with TB treatment and 
receipt of SMSs relating to TB treatment. Adverse events 
(AEs) due to inadvertent disclosure of a participant’s TB 
status will be monitored across study arms. Data will be 
captured through both (i) participant reports to HCWs at 
the facility level, and (ii) researchers asking participants 
at the telephone interview 12  months from enrolment. 
AEs disclosed by participants to facility HCWs will be 
recorded on facility social harms register.
Participation in the study is voluntary and can be halted 
at any time. All participants will continue to receive rou-
tine care even if they withdraw from using the DAT or 
the study but will be asked if their adherence and treat-
ment outcome data as well as their status 6 months after 
treatment completion can be collected.
Data management
ASCENT Ethiopia data will originate from three differ-
ent sources: the ASCENT adherence platform, ASCENT 
research database and ASCENT participant identifi-
ers database. For the ASCENT adherence platform, all 
patient identifiable data will be stored according to Ethi-
opian regulations related to storage of identifiable data. 
The ASCENT adherence platform will be hosted on the 
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Everwell Hub, a hosted web patient management applica-
tion. The platform is used by TB care providers to review 
patient medication adherence, track SMS communica-
tion with patients and, document adherence support 
actions. As part of privacy protection, user authentica-
tion and hierarchical user authorization are applied for 
accessing the ASCENT platform in addition to obtaining 
initial agreement from the patients. The Everwell Hub 
resides primarily on a Microsoft SQL database server and 
web servers located securely in the cloud.
The ASCENT research database and participant identi-
fiers database will be hosted in-country at KNCV Tuber-
culosis Foundation Ethiopia office, using REDCap [39], a 
secure web application for building and managing online 
surveys and databases.
Trial governance
A Technical Advisory Group (TAG) has been set up to 
provide oversight, monitor and oversee progress for the 
Ethiopia cluster randomized trial and companion studies 
in the Philippines, South Africa, Tanzania, and Ukraine. 
The TAG meets every 6 months and is composed of rep-
resentatives from the five countries and chaired by a sen-
ior researcher in Uganda.
A Community Advisory Board (CAB) has been estab-
lished in Ethiopia for the ASCENT project to oversee 
the research as well as all ASCENT activities in Ethiopia. 
The CAB’s main role will be to advise on study messag-
ing (support texts and reminders), the differentiated care 
plan and enhance communication between researchers 
and study community members.
A Trial Management Group meets regularly to over-
see the day-to-day activities of the research. The group 
includes the Trial Manager, representatives from the 
NTP in Ethiopia, LSHTM, KNCV Ethiopia, and KNCV 
the Netherlands. A representative from the Community 
Advisory Board will also attend the meeting once every 
2  months. The Trial Management Group is responsible 
for the trial design, leading the implementation, data 
analysis, publication, and determining authorship eligi-
bility, site training, study monitoring, and quarterly site 
visits.
Statistical analysis plan
Analyses of primary and secondary outcomes will follow 
intention-to-treat and per-protocol approach with meth-
ods appropriate for the clustered randomised trial design 
and will be based on two pair-wise comparisons of each 
intervention arm with the standard of care. The primary 
analysis will employ an individual-level logistic regres-
sion model with random effects (to account for within-
cluster variation) to estimate the intervention effect (odds 
ratio) and associated 95% confidence interval, adjusting 
for randomisation strata. Further adjustment for patient-
level covariates showing imbalance by study arm will be 
considered. Subgroup analyses will be conducted for the 
primary outcome and include urban/rural, gender, liter-
acy levels, socio-economic status, and type of health care 
provider. A full statistical analysis plan will be developed 
prior to the end of data collection.
Ethical consideration and dissemination
The trial has approval from London School of Hygiene & 
Tropical Medicine Ethics Committee (19120 - 1), United 
Kingdom; WHO Ethical Review Committee (0003297), 
Switzerland; Addis Ababa City Administration Health 
Bureau Public Emergency and Health Research Directo-
rate Institutional Review Board (A/A/H/B/1/978/227), 
and Oromia Regional Health Bureau Public Emergency 
and Health Research Directorate Institutional Review 
Board (BEFO/HBTFH/1-16/10322), Ethiopia. Writ-
ten informed consent from individuals to participate in 
the main effectiveness study will be collected by a TB 
care provider at the health facility. For the sub-studies, 
informed consent will be sought by research staff prior 
to interview. A unique study identifier will be assigned 
to each individual who has consented to the study. 
Anonymized individual-level data with only the unique 
study identifier will be visible to enable project/research 
staff to monitor study activities and evaluate fidelity to 
the intervention. All databases will be secured with pass-
word-protected access systems. All paper records will be 
stored at the participating clinics in locked filing cabinets 
and access to the records will be restricted to specified 
study team members. Any study related documents will 
be identified using the participant’s study number only, 
with locator information stored separately and available 
only to facility staff and research staff contacting partici-
pants at 12  months. All identifiers are stored in a data-
base with password-protected limited access.
The primary results from the main trial will be pre-
sented to national stakeholders, and disseminated to the 
Community Advisory Board, stakeholders, and partici-
pants through meetings and policy brief. Findings from 
the trial will also be presented at conferences and pub-
lished as articles for suitable scientific journals. All de-
identified research datasets will be shared for the sake 
of transparency and reproducibility. Data sharing agree-
ments will be developed taking into account Ethiopian-
specific data sharing regulations and to prioritize work 
led by researchers in Ethiopia.
Major changes to the study will be updated in the pro-
tocol and trial registration, reported to the ethics com-
mittees for approval, and communicated to the CAB and 
TAG without delay.
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Sub‑studies
We will conduct a total of four sub-studies, of which 
three will be conducted in selected facilities participat-
ing in the trial, among a subgroup of pulmonary DS-TB 
participants, HCWs and key stakeholders. In sub-study 
1, patient and facility-level acceptability and cost sur-
vey data will be collected. Sub-study 2, using qualitative 
methods, will focus on exploring patient experiences of 
taking TB treatment using a DAT. In sub-study 3, a quali-
tative study of the acceptability and feasibility of DAT will 
be conducted through interviews with health care work-
ers and key stakeholders. These sub-studies will contrib-
ute to the process evaluation of the interventions that will 
inform program implementation. The fourth sub-study 
will focus on enrolling DR-TB participants from DR-TB 
treatment facilities to measure acceptability of the DAT 
systems (smart pill box and video supported treatment).
Baseline assessment of the clusters in the trial
In collaboration with the NTP, a total of 78 health facili-
ties from the two regions in Ethiopia have been identified 
to participate in the ASCENT project. All the 36 facilities 
from Addis Ababa were urban health centres. The health 
facilities in Oromia included five urban primary hospi-
tals, five rural health centres and 32 urban health centres. 
An average of 63 (range 30–142 in Addis Ababa; 34–132 
in Oromia) pulmonary TB patients in these facilities were 
started on treatment in 2018. Nearly 60% (Addis Ababa) 
and 52% (Oromia) of these patients had bacteriologically 
confirmed PTB.
Preliminary findings from run‑in phase
Due to the large number of clusters, a staggered approach 
over a 5-month period was employed to include facilities 
in the run-in phase. The study tools and activities to be 
employed during the research period were implemented 
and piloted to ensure full operationality of the interven-
tion at the beginning of the research period. Participants 
enrolled during this phase will be followed up to the end 
of treatment. Over 1250  TB patients were screened for 
eligibility across all study arms and 586 enrolled, of which 
40% are females, median age 30 years (interquartile range 
23–40 years) and 67% had smear confirmed TB.
Discussion
This trial is a pragmatic cluster-randomised trial and 
the first of its kind to evaluate effectiveness of smart-pill 
box and medication labels linked to a web-based adher-
ence platform with differentiated response to patient 
adherence in Ethiopia. The aim of this trial extends 
beyond reducing the proportion of poor end of TB treat-
ment outcomes to include evaluating the 6-month dis-
ease free survival, process evaluation, and the wider 
epidemiological impact and cost-effectiveness of DAT 
systems for DS-TB patients.
Previous trials evaluating the effectiveness of DAT on 
treatment outcomes have shown mixed results [18, 20–
22]. Findings from trials in Pakistan, China and Cam-
eroon suggested that text messaging reminders have 
neither improved medication adherence [21, 22] nor 
did they increase treatment success and cure propor-
tions [18]. A trial in Ethiopia found mobile phone-based 
weekly refilling with daily medication reminder system 
improved medication adherence but with no signifi-
cant effect on treatment success [23]. However, another 
trial from China indicated that text messaging positively 
impacted treatment completion rate and negatively influ-
enced missed dose rate and interrupted treatment rate 
[20] and a trial conducted in Kenya assessing a text mes-
saging intervention demonstrated a reduction in unsuc-
cessful treatment outcome, mainly though reducing loss 
to follow-up [24]. Similarly, a cluster-randomised trial 
from China revealed reminders from medication moni-
tors improved medication adherence in TB patients [21]. 
Finally, a stepped-wedge CRT trial in Uganda showed 
no impact of the medication sleeves DAT intervention 
on successful treatment outcomes in an intent to treat 
analysis (all patients initiated on TB treatment) though 
did demonstrate a three-fold increase in odds of success-
ful outcomes in an analysis restricted to patients who did 
enrol onto the DAT in the intervention phase [19].
While RCTs are regarded as the “gold standard” in eval-
uating the specific interventions [33], the optimised study 
conditions make inference regarding their real-world 
effectiveness problematic [40]. Using the Pragmatic 
Explanatory Continuum Indicator Summary (PRECIS-2) 
tool [41] that measures trial design features, we argue 
that key aspects of our trial the manner of enrolment, 
eligibility criteria, delivery of the intervention (primar-
ily implemented by health facility staff), measurement of 
some outcomes, and process evaluation are pragmatic, 
and our findings have more relevance to directly inform 
DAT scale-up in countries.
In countries around the world, patients and their pro-
viders face several challenges with facility-based DOTs 
[4–7]. The need for patients to visit a health facility on 
either a daily or a weekly basis places a significant bur-
den on both the patient and the health system. Given the 
variety of patient needs to complete treatment, the tra-
ditional DOTs approach may not be sufficient to provide 
an adequate patient-centred model to support treatment. 
Thus, alternative approaches such as DATs to enhance 
current practices are needed.
DATs paired with an overarching adherence platform 
may help to overcome health care disparities by allowing 
patients greater freedom to self-manage and participate 
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in their own care, reduce financial burdens, and restore 
autonomy and dignity, while simultaneously empowering 
providers with more reliable and timelier patient data to 
inform care decisions for those patients with the greatest 
need. In addition, such platforms allow TB programs to 
integrate and aggregate data generated by different types 
of DATs. Additional benefits to the health system could 
also be gained upon successful implementation of DATs 
at times of unprecedented global health threats that 
challenge the routine health care services. For instance, 
in the era of COVID-19 pandemic, the standard of care 
has changed, in particular DOT, and DATs have been 
widely recommended to be ensure adequate treatment 
and adherence support [42, 43]. However, DATs may be 
least accessed by the priority populations for whom they 
are intended, due to limited access to mobile phones 
[44], low literacy and social support [27], resulting in dif-
ferential uptake to interventions based on the form of 
technology.
The ASCENT project has set primary and secondary 
outcomes, which are well characterized and relevant for 
TB management, and that allow for rigorous evaluation 
of the effectiveness and feasibility of DAT systems to 
improve disease-free survival among adult pulmonary 
TB participants in Ethiopia. Furthermore, the costing 
component of the ASCENT project enables us to analyse 
the cost-effectiveness of the intervention within the trial 
population as well as the patient costs averted. By imple-
menting this project to improve adherence, we hope to 
generate evidence to improve treatment completion 
and reduce rates of loss to follow-up, while reducing TB 
patient costs. If successful, this evaluation will generate 
further evidence for optimal use and scale-up of DATs in 
Ethiopia and elsewhere.
Trial status
The protocol is version 2.1.1, dated 31 March 2021. The 
trial started recruitment to the run-in phase on Decem-
ber 23, 2020. Recruitment to the main trial started in 
June 2021 and will continue for 12 months.
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